

Castle Biosciences invites you to attend the following non-CME presentation at the
Virginia Chapter, American College of Surgeons 2022 Annual Meeting

Updates on Gene Expression Profiling in Cutaneous Melanoma and Squamous Cell Carcinoma

Date

Friday, April 29

Time

6:45pm

Location

Kingsmill Resort
The Elements Room

Speaker



Dr. Peter Prieto

MD, MPH, CMQ, FACS, FSSO

Surgical Oncologist
University of Rochester Medical Center

Confirmed time & location on the finalized conference agenda.



Decision Dx

► Melanoma

Predicts individual risk in cutaneous melanoma patients recurrence or metastasis including the likelihood of sentinel lymph node positivity



Decision Dx
MyPath | DiffDx
► Melanoma

Improves diagnostic resolution in melanocytic lesions of uncertain malignant potential



Decision Dx

► SCC

Accurately identifies the risk of metastasis in high-risk squamous cell carcinoma patients with one or more risk factors



Additional Presentation Details

Peter Prieto, MD, MPH, FACS

Dr. Prieto, completed his general surgery residency at Yale University School of Medicine where he took three years off and completed a surgical oncology research fellowship and a one of its kind immunotherapy fellowship in the surgery branch of the National Cancer Institute, National Institutes of Health under the mentorship of Dr. Steven A. Rosenberg where he was co-investigator on numerous clinical trials.

He went on to complete his chief residency at Yale and then completed a two-year clinical complex surgical oncology fellowship at the prestigious and consistently ranked #1 Cancer Center in the United States, University of Texas MD Anderson Cancer Center in Houston, TX where he spent an additional year doing a post-doctoral research fellowship under the mentorship of Drs. Jennifer A. Wargo and Funda Meric-Bernstam. At MD Anderson, Dr. Prieto was instrumental in the development and analysis of a novel phase II trial looking at neoadjuvant targeted therapy in high-risk resectable stage III BRAF mutant melanoma, which has changed the practice in this challenging patient population.

Dr. Prieto is triple board certified in complex general surgical oncology, general surgery and medical quality. As a fully trained tumor immunotherapist and surgical oncologist, he has expertise in the treatment of primary, regionally advanced and metastatic melanoma, soft tissue sarcoma and breast cancer. His research interests and laboratory investigate mechanisms of immune evasion by solid tumors to targeted and immune checkpoint blockade and prognostic markers of response to immune based therapies including adoptive cell therapy (including melanoma, sarcoma, cholangiocarcinoma and breast cancer).

Dr. Prieto serves on the Society of Surgical Oncology's Sarcoma Disease Site Workgroup Committee and is the Cancer Center Physician Liaison to the American College of Surgeons Committee on Cancer.